MERKEL, CARLO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 24.113
AS - Asia 13.443
EU - Europa 6.153
AF - Africa 2.503
SA - Sud America 2.333
OC - Oceania 245
Continente sconosciuto - Info sul continente non disponibili 110
AN - Antartide 1
Totale 48.901
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 22.933
SG - Singapore 4.400
CN - Cina 2.126
VN - Vietnam 1.752
HK - Hong Kong 1.572
BR - Brasile 1.376
FI - Finlandia 723
IT - Italia 721
FR - Francia 708
DE - Germania 491
PL - Polonia 470
IN - India 420
SE - Svezia 377
UA - Ucraina 317
IQ - Iraq 267
TR - Turchia 261
RU - Federazione Russa 251
BD - Bangladesh 231
GB - Regno Unito 227
AR - Argentina 201
PK - Pakistan 172
PH - Filippine 168
ID - Indonesia 159
SA - Arabia Saudita 159
EC - Ecuador 123
UZ - Uzbekistan 114
NL - Olanda 112
CO - Colombia 111
ZA - Sudafrica 111
MX - Messico 109
VE - Venezuela 109
IE - Irlanda 104
MA - Marocco 97
AO - Angola 94
ES - Italia 92
ET - Etiopia 92
LB - Libano 91
JP - Giappone 89
MY - Malesia 88
CA - Canada 86
TN - Tunisia 86
GR - Grecia 85
PY - Paraguay 85
AT - Austria 81
CR - Costa Rica 81
DZ - Algeria 81
KE - Kenya 80
PS - Palestinian Territory 79
BJ - Benin 78
AM - Armenia 76
AZ - Azerbaigian 76
JO - Giordania 76
AL - Albania 75
AE - Emirati Arabi Uniti 72
KR - Corea 72
PT - Portogallo 70
MD - Moldavia 69
PE - Perù 69
RO - Romania 69
EG - Egitto 68
IL - Israele 68
HN - Honduras 67
NP - Nepal 67
CL - Cile 66
NZ - Nuova Zelanda 66
TT - Trinidad e Tobago 66
UY - Uruguay 66
BY - Bielorussia 65
CM - Camerun 65
MR - Mauritania 65
DO - Repubblica Dominicana 64
KG - Kirghizistan 64
KZ - Kazakistan 64
BF - Burkina Faso 63
BO - Bolivia 63
CI - Costa d'Avorio 63
DJ - Gibuti 63
SN - Senegal 63
TH - Thailandia 63
SK - Slovacchia (Repubblica Slovacca) 62
SO - Somalia 62
YT - Mayotte 62
CY - Cipro 61
GH - Ghana 61
ME - Montenegro 61
ZM - Zambia 61
DK - Danimarca 60
GF - Guiana Francese 60
JM - Giamaica 60
BA - Bosnia-Erzegovina 59
GA - Gabon 59
MK - Macedonia 59
MU - Mauritius 59
NO - Norvegia 59
SI - Slovenia 59
CV - Capo Verde 58
CW - ???statistics.table.value.countryCode.CW??? 58
NI - Nicaragua 58
AU - Australia 57
CG - Congo 57
Totale 46.115
Salva come PNG Salva come JPEG
Città #
Fairfield 2.598
Singapore 2.464
San Jose 2.311
Ashburn 1.861
Woodbridge 1.848
Houston 1.643
Hong Kong 1.446
Ann Arbor 1.406
Chandler 1.327
Jacksonville 1.105
Wilmington 1.066
Seattle 936
Cambridge 887
Boardman 532
Princeton 523
Ho Chi Minh City 498
Santa Clara 443
Hanoi 390
Bytom 383
Lauterbourg 331
Helsinki 306
Medford 287
Beijing 278
San Diego 261
Los Angeles 243
Nanjing 224
Dong Ket 165
Des Moines 164
Roxbury 148
Guangzhou 139
São Paulo 110
New York 108
Baghdad 103
Tashkent 92
Da Nang 89
Dublin 89
Luanda 78
Addis Ababa 77
Chicago 76
Norwalk 75
Shenyang 73
Hebei 71
Amman 69
Baku 69
Changsha 69
Cotonou 69
Nairobi 66
Nanchang 66
Padova 66
Yerevan 64
Dakar 62
Istanbul 62
Haiphong 60
Rome 60
Abidjan 59
Libreville 59
Munich 59
Nouakchott 59
Managua 58
San José 58
Lahore 57
Vienna 57
Lusaka 56
Accra 55
Montevideo 55
Ulan Bator 54
Bishkek 52
Bridgetown 52
Castries 52
Conakry 52
Jiaxing 52
Panama City 52
Council Bluffs 51
Podgorica 51
Kampala 50
Tirana 50
Antananarivo 49
Guayaquil 49
Buffalo 48
Cayenne 48
Djibouti 48
Phnom Penh 48
Riga 48
Tianjin 48
Tokyo 48
Vientiane 48
Dushanbe 47
Riyadh 47
Praia 46
Jeddah 44
Kigali 44
Kuala Lumpur 44
Noumea 44
Johannesburg 43
Kinshasa 43
Lilongwe 43
London 43
Minsk 43
Ouagadougou 43
Andorra la Vella 42
Totale 30.334
Salva come PNG Salva come JPEG
Nome #
The animal naming test: An easy tool for the assessment of hepatic encephalopathy 310
The self-morningness/eveningness (Self-ME): An extremely concise and totally subjective assessment of diurnal preference 268
A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis 257
Liver Fibrosis and Steatosis in Alstrom Syndrome: A Genetic Model for Metabolic Syndrome 246
Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension 235
Lowering portal pressure improves outcomes of patients with cirrhosis, with or without ascites: a meta-analysis. 235
Training of Italian emergency medicine residents in prehospital emergency medicine:state of the art and perspectives of improvement 235
A SIMPLIFIED PSYCHOMETRIC EVALUATION FOR THE DIAGNOSIS OF MINIMAL HEPATIC ENCEPHALOPATHY 234
Clinical value of asterixis in 374 well-characterised patients with cirrhosis and varying degree of hepatic encephalopathy 234
Acute liver rejection: Accuracy and predictive values of Doppler US measurements - Initial experience 233
Interobserver and inter-equipment variability of echo-Doppler sonographic evaluation of the superior mesenteric artery. 230
Increased myoendothelial gap junctions mediate the enhanced response to epoxyeicosatrienoic acid and acetylcholine in mesenteric arterial vessels of cirrhotic rats. 228
Nutrition and survival in patients with liver cirrhosis 225
Cost-effectiveness analysis of beta-blockers vs endoscopic surveillance in patients with cirrhosis and small varices 222
Squamous cell carcinoma antigen-1 (SERPINB3) polymorphism in chronic liver disease 222
Long-term effects of beta-adrenergic blockade with nadolol on hepatic and renal haemodynamics and function in cirrhotics. 220
Haeme oxygenase mediates hyporeactivity to phenylephrine in the mesenteric vessels of cirrhotic rats with ascites 219
A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis 217
Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference 217
Should we routinely measure portal pressure in patients with cirrhosis, using hepatic venous pressure gradient (HVPG) as guidance for prophylaxis and treatment of bleeding and re-bleeding? Yes! 216
Incidence and natural history of small esophageal varices in cirrhotic patients 215
Electroencephalography in patients with cirrhosis. 208
Covert hepatic encephalopathy: Agreement and predictive validity of different indices 208
Change in portal flow after liver transplantation: effect on hepatic arterial resistance indices and role of spleen size 207
Analisi costo-efficacia della terapia con beta-bloccanti in profilassi primaria del sanguinamento gastrico in pazienti cirrotici con varici esofagee F1 205
Ammonia-related changes in cerebral electrogenesis in healthy subjects and patients with cirrhosis. 204
Effect of somatostatin on splanchnic hemodynamics in patients with liver cirrhosis and portal hypertension. 203
Blood flow of experimental liver metastases in rat as evaluated by the locally injected 133-Xenon washout. 201
Effect of somatostatin on liver blood flow and liver metabolic activity in patients with cirrhosis. 200
Switch therapy with ciprofloxacin vs. intravenous ceftazidime in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis: similar efficacy at lower cost 198
Prognostic Benefit of the Addition of a Quantitative Index of Hepatic Encephalopathy to the MELD score: the MELD-EEG 197
Renal water and sodium handling in compensated liver cirrhosis: mechanism of the impaired natriuresis after saline loading. 197
Hepatitis C Virus Reinfection in Liver Transplant Patients: Evaluation of Liver Damage Progression with Echo-Color Doppler 197
AISF practice guidelines for portal hypertension.Committee for portal hypertension of the Italian Association for the Study of the Liver. 196
Carbon monoxide-mediated activation of large-conductance calcium-activated potassium channels contributes to mesenteric vasodilatation in cirrhotic rats 196
Clinical significance of worsening portal hypertension during long-term medical treatment in patients with cirrhosis who had been classified as early good-responders on haemodynamic criteria 195
Splenic Doppler impedance indices: influence of different portal hemodynamic conditions. 195
New abdominal collaterals at ultrasound: A clue of progression of portal hypertension 195
Carbohydrate and lipid metabolism in cirrhosis. Evidence that hepatic uptake of gluconeogenic precursors and of free fatty acids depends on effective hepatic flow. 194
EVALUATION OF SPLANCHNIC ANGIOGRAPHY AS A PROGNOSTIC INDEX OF SURVIVAL IN PATIENTS WITH CIRRHOSIS 193
Visual attention in cirrhotic patients: a study on covert visual attention orienting. 191
Hepatitis C virus reinfection in liver transplant patients: evaluation of liver damage progression with echo-color doppler. 187
HCV genotype 3 and squamous cell carcinoma antigen (SCCA)-IgM are independently associated with histological features of NASH in HCV-infected patients 186
Different hemodynamic patterns of alcoholic and viral endstage cirrhosis: analysis of explanted liver weight, degree of fibrosis and splanchnic Doppler parameters 186
Revising consensus in portal hypertension: Report of the Baveno V consensus workshop on methodology of diagnosis and therapy in portal hypertension 185
Spontaneous portosystemic shunts in cirrhosis: Detection, implications, and clinical associations 184
Beta-blockers in the prevention of aggravation of esophageal varices in patients with cirrhosis and small varices: a placebo-controlled clinical trial. 182
Confounders in the detection of minimal hepatic encephalopathy: a neuropsychological and quantified EEG study. 181
SERPINB3 is associated with longer survival in transgenic mice. 181
Sleep-wake abnormalities in patients with cirrhosis. 179
Prognostic value of hypozincemia in cirrhotic patients 179
Simple tools for complex syndromes: A three-level difficulty test for hepatic encephalopathy 178
Effects of isosorbide dinitrate on portal hypertension in alcoholic cirrhosis. 177
Prevalence and prognostic value of quantified electroencephalogram (EEG) alterations in cirrhotic patients 177
Renal effects of nadolol in cirrhosis. 176
Prognostic benefit of the addition of an electroencephalographic (EEG) index to the MELD score: the MELD-EEG. 175
A short cut to predict the clinical response to beta-blocker therapy in cirrhosis? 174
Adding beta-blockers to sclerotherapy in the prevention of variceal rebleeding: a meta-analysis assessment. 174
Theophylline pharmacokinetics and liver function indexes in chronic liver disease. 174
Metabolic control of kidney hemodynamics in normal and insulin-dependent diabetic subjects. Effects of acetoacetic, lactic, and acetic acids. 173
HFE, TGF-BETA1 AND SQUAMOUS CELL CARCNOMA ANTIGEN-1 POLYMORPHISMS AND LIVER DISEASE STAGE IN CHRONIC HCV INFECTION 171
Nadolol for prevention of variceal rebleeding in cirrhosis: a controlled clinical trial. 170
Excessive daytime sleepiness and hepatic encephalopathy: it is worth asking. Metab Brain Dis. 2013 Jun;28(2):245-8. doi: 10.1007/s11011-012-9360-4. Epub 2012 Nov 18. PMID: 23180317 [PubMed - indexed for MEDLINE] 168
Portal hypertension and portal hypertensive gastropathy in patients with liver cirrhosis: a haemodynamic study 168
Encephalopathy or hepatic encephalopathy? 168
Value of prealbumin plasma levels as liver test. 167
Effects of chronic therapy with nadolol on portal hemodynamics and on splanchnic impedance indices using Doppler sonography: Comparison between acute and chronic effects 167
Renal haemodynamics in essential hypertension assessed by 133-Xenon washout and selective renal angiography 167
Cost-effective analysis of primary prophylaxis of variceal bleeding with beta-blockers vs. endoscopic surveillance in cirrhotic patients with small esophageal varices. 167
Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. 166
Agreement and predictive validity of neurophysiological, psychometric, and psychophysical indices of hepatic encephalopathy. 166
Comparison between two high-dose methylprednisolone schedules in the treatment of acute hepatic cellular rejection in liver transplant recipients: a controlled clinical trial 165
The Influence of Environmental Factors on Sleep Quality in Hospitalized Medical Patients 164
Aminopyrine breath test in the prognostic evaluation of patients with cirrhosis. 162
Heme oxygenase regulates renal arterial resistance and sodium excretion in cirrhotic rats 162
Cognitive Impairment and Electroencephalographic Alterations Before and After Liver Transplantation: What Is Reversible? 162
Bright times for patients with cirrhosis and delayed sleep habits: a case report of the beneficial effect of light therapy 160
Hemodynamic and clinical evaluation of nadolol in the treatment of portal hypertension in patients with cirrhosis. 160
Aminopyrine breath test improves prognostic ability of Pugh score in cirrhosis. 160
A COST-EFFECTIVENESS ANALYSIS OF PROPHYLAXIS OF VARICEAL BLEEDING STARTING FROM SMALL ESOPHAGEAL VARICES COMPARED TO SURVEILLANCE AND TREATMENT STARTING FROM LARGE ONES 158
Natural History of cirrhotic patients with small esophageal varices: a prospective study 158
QUANTIFICAZIONE DEL DANNO EPATICO ACUTO DA CHEMIOEMBOLIZZAZIONE PER EPATOCARCINOMA SU CIRROSI. 157
PGE2 urinary escretion and renal haemodynamics after nadolol treatment of portal hypertension in patients with liver cirrhosis. 157
Attention: Minimal hepatic encephalopathy and road accidents 157
Tubular site of renal sodium retention in ascitic liver cirrhosis evaluated by lithium clearance. 157
Interobserver and interequipment variability of hepatic, splenic, and renal arterial Doppler resistance indices in normal subjects and patients with cirrhosis. 157
PLASMA CARNITINE LEVELS IN LIVER-CIRRHOSIS - RELATIONSHIP WITH NUTRITIONAL-STATUS AND LIVER-DAMAGE 156
Intrarenal blood flow, circulation time, and cortical vascular volume in patients with cirrhosis. 156
Effect of nadolol on liver haemodynamics and function in patients with cirrhosis. 156
Heme oxygenase regulates the response of intrarenal arteries to alpha-adrenergic stimulation in experimental cirrhosis. 155
Enhanced renal sympathetic tone in liver cirrhosis: evaluation by intrarenal administration of dihydroergocristine. 155
L'impiego dei beta-bloccanti nell'ipertensione portale in corso di cirrosi epatica: efficacia ed applicabilità. 154
The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis 154
POLIMORFISMO DI SCCA (SQUAMOUS CELL CARCINOMA ANTIGEN) E PROGRESSIONE DELLA MALATTIA EPATICA NELL’INFEZIOE HCV 153
IgM-linked SerpinB3 and SerpinB4 in Sera of Patients with Chronic Liver Disease 153
Hemodynamic and clinical evaluation of nadolol in the treatment of portal hypertension in patients with cirrhosis. 153
Covert hepatic encephalopathy: does the mini-mental state examination help? 153
Renal function in congestive heart failure. 153
Noninvasive grading of the severity of portal hypertension in cirrhotic patients by echo-color-Doppler 153
Vasoactive factors and hemodynamic mechanisms in the pathophysiology of portal hypertension in cirrhosis 152
Totale 18.703
Salva come PNG Salva come JPEG
Categoria #
all - tutte 133.307
article - articoli 102.037
book - libri 1.312
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 8.134
Totale 244.790
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021635 0 0 0 0 0 0 0 0 0 0 315 320
2021/20223.523 56 573 363 212 186 168 132 353 207 52 340 881
2022/20232.908 692 241 79 278 489 434 3 183 341 17 111 40
2023/20241.079 63 203 99 84 57 55 33 33 43 23 190 196
2024/20256.372 9 477 320 258 1.000 116 243 407 598 239 1.083 1.622
2025/202621.996 545 2.212 3.493 3.319 1.812 951 2.815 2.195 2.711 1.478 465 0
Totale 48.981